Legacy App users can now access the Health Portal – just reset your password using email as username.

Are Occasional Steroid Blasts Worth the Risk on TRT?

Are Occasional Steroid Blasts Worth the Risk on TRT?

Viewing This Video Is A Member Exclusive Feature

But you don’t need membership to get Dr. O’Connor’s insight on this topic, it’s in the summary, key takeaways, and related drugs and conditions below.

Want to watch the full video? Join the Health Portal Today.

Join Now

Timeline

Timestamp
Topic
00:00
A viewer asks whether adding one or two mild steroid blasts each year to TRT is harmful. Dr. O’Connor introduces blasting and cruising and explains suppression of the hormonal signals that regulate natural testosterone production.
01:55
The discussion traces the move from separate steroid cycles to maintaining a testosterone base between higher-dose periods. Dr. O’Connor distinguishes cruising from physiological replacement and describes how a blast may involve increasing testosterone or adding another anabolic steroid.
04:05
The response turns from drug choices to blood pressure, heart structure, ejection fraction, and diastolic function. Kidney assessment follows, with proteinuria and urine albumin testing presented as important information beyond blood-based estimates of filtration.
05:50
Dr. O’Connor expands on urine protein, kidney concerns during Anavar use, and the additional burden of hypertension. Brief references to Jardiance and Farxiga lead into his warning that repeated exposures can accumulate before an obvious complication appears.
07:20
The closing remarks consider harder training and limiting testosterone exposure as alternatives to adding another blast. Dr. O’Connor returns to heart and kidney health reserve, emphasizing uncertainty about individual harm and the goal of preserving long-term health.

Video Summary

Returning to TRT after an occasional steroid blast does not erase the additional exposure or establish that the practice is harmless. Dr. Thomas O’Connor responds to a viewer asking whether one or two “mild” blasts each year could fit within an otherwise healthy testosterone regimen.

The discussion begins with blasting and cruising and the suppression of natural hormone production during continued androgen use. Dr. O’Connor describes how some men move from separate cycles to maintaining testosterone between higher-dose periods, while distinguishing the doses used in bodybuilding from physiological replacement.

He then examines two ways a blast may be added to a testosterone base: increasing testosterone itself or adding another anabolic steroid. Although several drugs are named, the response does not establish a safe combination or provide a personalized endorsement.

Heart and kidney health become the central concerns. Dr. O’Connor discusses blood pressure, heart structure, ejection fraction, diastolic dysfunction, and urine protein, emphasizing that reassuring blood-based kidney estimates do not answer every question about kidney health.

Anavar receives particular attention during the kidney discussion, followed by brief mentions of Jardiance and Farxiga as medicines used in his clinical practice. The broader point is to investigate underlying risks rather than assume that a relatively small addition is inconsequential.

The closing response frames the decision around cumulative strain on what Dr. O’Connor calls heart and kidney “health reserve.” He encourages attention to training and limiting testosterone exposure, while acknowledging that no one can predict exactly how much harm an occasional blast will cause an individual.

Drug Callouts

Drug
Description
Testosterone
Testosterone is an androgen hormone prescribed as replacement therapy for testosterone deficiency and also used nonmedically for muscle and performance gains. It forms the continuing base in the viewer’s proposed regimen, allowing Dr. O’Connor to distinguish replacement from additional exposure during a blast.
Anavar (Oxandrolone)
Anavar is a brand name for oxandrolone, an oral anabolic-androgenic steroid. After naming it as a possible addition to testosterone, Dr. O’Connor returns to it during the discussion of kidney health, urine protein, and the tradeoffs of further steroid exposure.

Condition Callouts

Condition
Description
Hypertension
Hypertension is persistently elevated blood pressure that places strain on blood vessels and organs. Blood pressure anchors Dr. O’Connor’s assessment of the proposed blasts and reappears as a concern alongside changes in heart function and urine protein.
Diastolic Dysfunction
Diastolic dysfunction is impaired relaxation or filling of the heart between beats. Dr. O’Connor raises it when explaining why echocardiographic assessment after steroid exposure involves more than checking the ejection fraction alone.
Proteinuria
Proteinuria is an abnormally increased amount of protein in the urine and can indicate kidney damage. The kidney discussion emphasizes urine testing because a reassuring estimated filtration rate does not address whether protein is being lost.
Focal Segmental Glomerulosclerosis
Focal segmental glomerulosclerosis is a pattern of scarring that affects portions of some of the kidney’s filtering units. It is named while discussing proteinuria and possible kidney complications, without establishing that the viewer has this condition.

Key Takeaways

  • Returning to a lower testosterone dose after a blast reduces exposure but does not undo the higher-dose period or make the overall pattern harmless.
  • Returning to a lower testosterone dose after a blast reduces exposure but does not undo the higher-dose period or make the overall pattern harmless.
  • Blood pressure and heart function belong in the assessment of additional steroid use, even when other health markers appear favorable.
  • Urine protein testing and blood-based kidney filtration estimates provide different information, so one reassuring result does not replace the other.
  • Describing a blast as mild does not quantify its effect on an individual’s long-term heart or kidney health.
  • Current health measurements cannot predict exactly how much additional steroid exposure a person can tolerate without future harm.